Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
MOLECULIN BIOTECH INC (MBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.73+3.19%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MBRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash and equivalents above $7 million | Management has raised $9.3 million to sustain operations into early 2027. | Intact | Cash and equivalents fall below $5 million by Q1 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder: the company is loss-making, recent performance is weak, and management execution is volatile. The long-term thesis is in a watch state, with Part A dosing completed in the MIRACLE trial but the full efficacy readout still pending.
The valuation evidence describes MBRX as cheap versus peers, with medium confidence in that comparison. The snapshot gives no direct measure of what the market expects, so the expectations gap is unclear; a low fragility reading does not remove the business and funding risks.
Near term, erratic earnings and elevated miss risk leave results vulnerable, while a guidance cut or weaker jobs data could add pressure. Over the multi-year view, progress depends on clinical execution: Q2 research spending rose to support MIRACLE and other studies, but the comprehensive efficacy readout remains pending and other pipeline progress is not quantified. Financing extended the stated cash runway into Q1 2027, though management says significant additional funding is needed.
A favorable scenario would pair continued MIRACLE trial execution with positive efficacy evidence; sector momentum could also benefit from strength among healthcare bellwethers. The unfavorable case includes a guidance cut, further weak results, worsening economic conditions, or difficulty securing the additional funding needed for development.
Over the next 1 to 3 years, MBRX's thesis rests on clinical evidence and access to funding, against a backdrop of weak performance and elevated risk. The snapshot supports a cautious watch-state description, not a settled long-term thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Enrollment in the MIRACLE trial is on track to reach 90 patients by early 2027. |
| Intact |
| Enrollment falls below 74 patients by early 2027 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve significant interim trial results for Annamycin | A supporting condition in MOLECULIN BIOTECH INC's published investment case. The stated target is Complete remission rates three times higher than control. | Under Pressure | Interim trial results do not show significant improvement by mid-2027 | Interim data not significant vs 3x control target News reports MBRX interim cancer trial data fell short of significance in June 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.33 → $-23.40 · observed estimates
$0.04B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-07-25 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-07-26 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-07-27 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-07-28 | $-3.84 | $0 | 3 / 3 |
| 2026-07-29 | $-3.84 | $0 | 3 / 3 |
| 2026-07-30 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-07-31 | $-3.84 | $0 | 3 / 3 |
| 2026-08-01 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-02 | $-3.84 | $0 | 3 / 3 |
| 2026-08-03 | $-3.84 | $0 | 3 / 3 |
| 2026-08-04 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-05 | $-3.33 | $0 | 2 / 3 |
| 2026-08-06 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-07 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-08 | $-3.33 | $0 | 2 / 3 |
| 2026-08-09 | $-3.33 | $0 | 2 / 3 |
| 2026-08-10 | $-3.33 | $0 | 2 / 3 |
| 2026-08-12 | $-2.78 | $0 | 3 / 3 |
| 2026-08-13 | $-2.78 | $0 | 3 / 3 |
| 2026-08-14 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-15 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-16 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-17 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-18 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-19 | $-3.33 | $41,958,000 | 2 / 3 |
| 2026-08-20 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-21 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-22 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-23 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-24 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-25 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-26 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-27 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-28 | $-2.14 | $41,958,000 | 2 / 3 |
| 2026-08-29 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-08-30 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-08-31 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-01 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-02 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-03 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-04 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-05 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-06 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-07 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-08 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-09 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-10 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-11 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-12 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-13 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-14 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-15 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-16 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-17 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-18 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-19 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-20 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-21 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-22 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-23 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-24 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-25 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-26 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-27 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-28 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-29 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-09-30 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-01 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-02 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-03 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-04 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-05 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-06 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-07 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-08 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-09 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-10 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-11 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-12 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-13 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-14 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-15 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-16 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-17 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-18 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-19 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-20 | $-1.17 | $41,958,000 | 2 / 3 |
| 2026-10-21 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-22 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-23 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-24 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-25 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-26 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-27 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-28 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-29 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-30 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-10-31 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-11-01 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-11-02 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-11-03 | $-23.40 | $41,958,000 | 2 / 3 |
| 2026-11-04 | $-23.40 | $41,958,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.